Related references
Note: Only part of the references are listed.Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Laura Kalfeist et al.
CELLS (2022)
Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller
Giannis Mountzios et al.
CLINICAL LUNG CANCER (2021)
Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment
Ying Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
Riccardo Lobefaro et al.
LUNG CANCER (2021)
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
Wei Cao et al.
CHINESE MEDICAL JOURNAL (2021)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Hongchuan Zhang et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
Claudio Martin et al.
CLINICAL LUNG CANCER (2020)
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
Martin Svaton et al.
ANTICANCER RESEARCH (2020)
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer
Ou Yamaguchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Francesco Facchinetti et al.
EUROPEAN JOURNAL OF CANCER (2020)
Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status
Yuichi Adachi et al.
CANCER MEDICINE (2020)
Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases
Takehiro Tozuka et al.
THORACIC CANCER (2020)
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
Giulio Metro et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Leilei Ai et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
Andrea De Giglio et al.
CANCERS (2020)
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
Mariona Riudavets et al.
FRONTIERS IN ONCOLOGY (2020)
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma
Alexandra Drakaki et al.
ONCOIMMUNOLOGY (2020)
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Lizza E. L. Hendriks et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya et al.
INVESTIGATIONAL NEW DRUGS (2019)
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells
Natsumi Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Audrey Bellesoeur et al.
CANCERS (2019)
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Giovanni Fuca et al.
ESMO OPEN (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Susan C. Scott et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab
Coraline Dumenil et al.
PLOS ONE (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers
Lisa Hartling et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
Dyspnea in Palliative Care: Expanding the Role of Corticosteroids
Richard J. Lin et al.
JOURNAL OF PALLIATIVE MEDICINE (2012)
How to obtain the confidence interval from a P value
Douglas G. Altman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
Timothy C. Ryken et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)